# Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance

> **NCT03311958** · EARLY_PHASE1 · COMPLETED · sponsor: **Fox Chase Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Nivolumab, IV, 240 mg

## Key facts

- **NCT ID:** NCT03311958
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-15
- **Primary completion:** 2024-01-26
- **Final completion:** 2024-01-26
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03311958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03311958, "Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03311958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*